These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24757111)

  • 1. What can biomarkers tell us about cognition in Parkinson's disease?
    Mollenhauer B; Rochester L; Chen-Plotkin A; Brooks D
    Mov Disord; 2014 Apr; 29(5):622-33. PubMed ID: 24757111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic influences on cognitive decline in Parkinson's disease.
    Morley JF; Xie SX; Hurtig HI; Stern MB; Colcher A; Horn S; Dahodwala N; Duda JE; Weintraub D; Chen-Plotkin AS; Van Deerlin V; Falcone D; Siderowf A
    Mov Disord; 2012 Apr; 27(4):512-8. PubMed ID: 22344634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Nombela C; Rowe JB; Winder-Rhodes SE; Hampshire A; Owen AM; Breen DP; Duncan GW; Khoo TK; Yarnall AJ; Firbank MJ; Chinnery PF; Robbins TW; O'Brien JT; Brooks DJ; Burn DJ; ; Barker RA
    Brain; 2014 Oct; 137(Pt 10):2743-58. PubMed ID: 25080285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.
    Williams-Gray CH; Evans JR; Goris A; Foltynie T; Ban M; Robbins TW; Brayne C; Kolachana BS; Weinberger DR; Sawcer SJ; Barker RA
    Brain; 2009 Nov; 132(Pt 11):2958-69. PubMed ID: 19812213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.
    Paul KC; Rausch R; Creek MM; Sinsheimer JS; Bronstein JM; Bordelon Y; Ritz B
    J Parkinsons Dis; 2016 Apr; 6(2):349-59. PubMed ID: 27061069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The genetic predictors of cognitive impairment in Parkinson's disease].
    Senkevich KA; Miliukhina IV; Pchelina SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8):109-117. PubMed ID: 30251988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive decline in Parkinson disease.
    Aarsland D; Creese B; Politis M; Chaudhuri KR; Ffytche DH; Weintraub D; Ballard C
    Nat Rev Neurol; 2017 Apr; 13(4):217-231. PubMed ID: 28257128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
    Yousaf T; Pagano G; Niccolini F; Politis M
    J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.
    Collins LM; Williams-Gray CH
    Front Psychiatry; 2016; 7():89. PubMed ID: 27242557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognition in Parkinson's Disease.
    O'Callaghan C; Lewis SJG
    Int Rev Neurobiol; 2017; 133():557-583. PubMed ID: 28802933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinson's Disease Is Modified by the SNCA rs356181 Polymorphism.
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Neurodegener Dis; 2018; 18(5-6):233-238. PubMed ID: 30336481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.
    Fagan ES; Pihlstrøm L
    Eur J Neurol; 2017 Apr; 24(4):561-e20. PubMed ID: 28220571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for cognitive impairment in Parkinson disease.
    Shi M; Huber BR; Zhang J
    Brain Pathol; 2010 May; 20(3):660-71. PubMed ID: 20522092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.